GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Capex-to-Operating-Income

Hikma Pharmaceuticals (LSE:HIK) Capex-to-Operating-Income : 0.33 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Hikma Pharmaceuticals's Capital Expenditure for the six months ended in Dec. 2023 was £-76.63 Mil. Its Operating Income for the six months ended in Dec. 2023 was £229.89 Mil.

Hence, Hikma Pharmaceuticals's Capex-to-Operating-Income for the six months ended in Dec. 2023 was 0.33.


Hikma Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Hikma Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Capex-to-Operating-Income Chart

Hikma Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.40 0.38 0.47 0.34

Hikma Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.49 0.45 0.34 0.33

Competitive Comparison of Hikma Pharmaceuticals's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Capex-to-Operating-Income falls into.



Hikma Pharmaceuticals Capex-to-Operating-Income Calculation

Hikma Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-161.16) / 477.16
=0.34

Hikma Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-76.63) / 229.89
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hikma Pharmaceuticals  (LSE:HIK) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Hikma Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals (LSE:HIK) Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines